| Bid | 3.5 |
| Market Cap | 37.85M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.78 |
| PE Ratio (ttm) | -1.97 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 3.55 |
| Volume | 14,292 |
| Avg. Volume (20D) | 63,995 |
| Open | 3.65 |
| Previous Close | 3.49 |
| Day's Range | 3.45 - 3.74 |
| 52-Week Range | 2.79 - 11.99 |
| Beta | undefined |
About LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In ...
Analyst Forecast
According to 1 analyst ratings, the average rating for LTRN stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
2 months ago · businesswire.com
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesDALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machin...
2 months ago · businesswire.com
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory BoardDALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation,...
2 months ago · businesswire.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology ...
